Expand RIGL Menu
RIGL MENU

RIGL Latest Press Releases

-- January 12, 2026 --

Rigel Provides Business Update and 2026 Outlook PRNewswire 8:05 AM

-- January 9, 2026 --

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PRNewswire 8:05 AM

-- January 7, 2026 --

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference PRNewswire 8:05 AM

-- December 7, 2025 --

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition PRNewswire 9:30 AM

-- November 26, 2025 --

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference PRNewswire 8:05 AM

-- November 17, 2025 --

Rigel Announces Publication of Final 5-year Data on REZLIDHIA (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology PRNewswire 8:05 AM

-- November 12, 2025 --

Rigel to Present at the Jefferies Global Healthcare Conference in London PRNewswire 8:05 AM

-- November 4, 2025 --

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update PRNewswire 4:01 PM

-- November 3, 2025 --

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition PRNewswire 9:05 AM

-- October 29, 2025 --

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update PRNewswire 8:05 AM

-- October 8, 2025 --

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS PRNewswire 8:05 AM

-- October 3, 2025 --

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PRNewswire 8:05 AM

-- August 26, 2025 --

Rigel to Participate in Upcoming September Investor Conferences PRNewswire 8:05 AM
Market Data Delayed 15 Minutes